Literature DB >> 26037201

Intestinal mTOR regulates GLP-1 production in mouse L cells.

Geyang Xu1, Ziru Li, Li Ding, Hong Tang, Song Guo, Hongbin Liang, Huadong Wang, Weizhen Zhang.   

Abstract

AIMS/HYPOTHESIS: Glucagon-like peptide (GLP-1), an intestinal incretin produced in L cells through proglucagon processing, is released in response to meal intake. The intracellular mechanism by which L cells sense the organism energy level to coordinate the production of GLP-1 remains unclear. Mechanistic target of rapamycin (mTOR) is an intracellular fuel sensor critical for energy homeostasis. In this study, we investigated whether intestinal mTOR regulates GLP-1 production in L cells.
METHODS: The effects of mTOR on GLP-1 production were examined in lean- or high-fat diet (HFD) induced diabetic C57/BL6, db/db, Neurog3-Tsc1(-/-) mice, and STC-1 cells. GLP-1 expression was investigated by real-time PCR and western blotting. Plasma GLP-1 and insulin were detected by enzyme immunoassay and radioimmunoassay, respectively.
RESULTS: Fasting downregulated mTOR activity, which was associated with a decrement of intestinal proglucagon and circulating GLP-1. Upon re-feeding, these alterations returned to the levels of fed animals. In HFD induced diabetic mice, ileal mTOR signalling, proglucagon and circulating GLP-1 were significantly decreased. Inhibition of mTOR signalling by rapamycin decreased levels of intestinal and plasma GLP-1 in both normal and diabetic mice. Activation of the intestinal mTOR signalling by L-leucine or Tsc1 gene deletion increased levels of intestinal proglucagon and plasma GLP-1. Overexpression of mTOR stimulated proglucagon promoter activity and GLP-1 production, whereas inhibition of mTOR activity by overexpression of tuberous sclerosis 1 (TSC1) or TSC2 decreased proglucagon promoter activity and GLP-1 production in STC-1 cells. CONCLUSIONS/
INTERPRETATION: mTOR may link energy supply with the production of GLP-1 in L cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26037201     DOI: 10.1007/s00125-015-3632-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

Authors:  Mary Parks; Curtis Rosebraugh
Journal:  N Engl J Med       Date:  2010-02-17       Impact factor: 91.245

2.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.

Authors:  L B Knudsen; L Pridal
Journal:  Eur J Pharmacol       Date:  1996-12-30       Impact factor: 4.432

3.  The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription.

Authors:  T Jin; D J Drucker
Journal:  Mol Endocrinol       Date:  1995-10

4.  Mammalian TOR: a homeostatic ATP sensor.

Authors:  P B Dennis; A Jaeschke; M Saitoh; B Fowler; S C Kozma; G Thomas
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

5.  mTOR-dependent modulation of gastric nesfatin-1/NUCB2.

Authors:  Ziru Li; Geyang Xu; Yin Li; Jing Zhao; Michael W Mulholland; Weizhen Zhang
Journal:  Cell Physiol Biochem       Date:  2012-04-03

6.  Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Authors:  Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne S de Boer; Daniel J Drucker; Carsten Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C Moses; Anne-Marie Mølck; Henriette S Nielsen; Jette Nowak; Helene Solberg; Tu D L Thi; Milan Zdravkovic; Ulrik Moerch
Journal:  Endocrinology       Date:  2010-03-04       Impact factor: 4.736

7.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

8.  GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine.

Authors:  Kristine Mortensen; Louise Lundby Christensen; Jens Juul Holst; Cathrine Orskov
Journal:  Regul Pept       Date:  2003-07-15

9.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.

Authors:  Merav Fraenkel; Mali Ketzinel-Gilad; Yafa Ariav; Orit Pappo; Melis Karaca; Julien Castel; Marie-France Berthault; Christophe Magnan; Erol Cerasi; Nurit Kaiser; Gil Leibowitz
Journal:  Diabetes       Date:  2008-01-03       Impact factor: 9.461

View more
  7 in total

1.  Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease.

Authors:  Tamàs Fülöp; Usma Munawara; Anis Larbi; Mathieu Desroches; Serafim Rodrigues; Michele Catanzaro; Andrea Guidolin; Abdelouahed Khalil; François Bernier; Annelise E Barron; Katsuiku Hirokawa; Pascale B Beauregard; David Dumoulin; Jean-Philippe Bellenger; Jacek M Witkowski; Eric Frost
Journal:  CNS Drugs       Date:  2020-07       Impact factor: 6.497

2.  Acute selective bioactivity of grape seed proanthocyanidins on enteroendocrine secretions in the gastrointestinal tract.

Authors:  Àngela Casanova-Martí; Joan Serrano; M Teresa Blay; Ximena Terra; Anna Ardévol; Montserrat Pinent
Journal:  Food Nutr Res       Date:  2017-06-07       Impact factor: 3.894

3.  Intestinal Epithelial-Specific mTORC1 Activation Enhances Intestinal Adaptation After Small Bowel Resection.

Authors:  Lauren Barron; Raphael C Sun; Bola Aladegbami; Christopher R Erwin; Brad W Warner; Jun Guo
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-12-10

4.  MicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells.

Authors:  Jiao Wang; Di Zhao; Cheng-Zhi Ding; Feng Guo; Li-Na Wu; Feng-Jiao Huang; Yan-Ling Liu; Shui-Ying Zhao; Ying Xin; Sheng-Nan Ma; Hong-Fei Ji; Xiang Wang; Li-Rui Wei
Journal:  Cell Death Dis       Date:  2021-01-21       Impact factor: 8.469

5.  Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion.

Authors:  Liusong Yang; Lina Wang; Canjun Zhu; Junguo Wu; Yexian Yuan; Lulu Yu; Yaqiong Xu; Jingren Xu; Tao Wang; Zhengrui Liao; Songbo Wang; Xiaotong Zhu; Ping Gao; Yongliang Zhang; Xiuqi Wang; Qingyan Jiang; Gang Shu
Journal:  Oncotarget       Date:  2017-08-03

6.  Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.

Authors:  Xiaowen Zhang; Fei Shao; Lin Zhu; Yuyang Ze; Dalong Zhu; Yan Bi
Journal:  BMC Pharmacol Toxicol       Date:  2018-09-17       Impact factor: 2.483

Review 7.  Mechanisms controlling hormone secretion in human gut and its relevance to metabolism.

Authors:  Alyce M Martin; Emily W Sun; Damien J Keating
Journal:  J Endocrinol       Date:  2019-11-29       Impact factor: 4.286

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.